Report overview
Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to medical or surgical treatment. Risk factor for castration resistant prostate cancer includes genetic predisposition, geriatric population, unhygienic diet, medication exposure and many sexual partners. Diagnosis for the detection of castration resistant prostate cancer includes prostate imaging, biopsy, tumor marker and staging test. Crucial factor about castration resistant prostate cancer is that it is resistant to medical and surgical treatment. However, other treatment options that are available in the market include hormone therapy, immune modulation, antiangiogenic treatment and bone targeted therapies.
This report contains market size and forecasts of Castration Resistant Prostate Cancer Treatment in Global, including the following market information:
Global Castration Resistant Prostate Cancer Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Castration Resistant Prostate Cancer Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hormonal Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Castration Resistant Prostate Cancer Treatment include Active Biotech, Diagnocure, Glaxosmithkline, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceuticals, Abbott Laboratories and Bayer Healthcare Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Castration Resistant Prostate Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Castration Resistant Prostate Cancer Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Castration Resistant Prostate Cancer Treatment Market Segment Percentages, by Type, 2021 (%)
Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others
Global Castration Resistant Prostate Cancer Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Castration Resistant Prostate Cancer Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Ambulatory Surgical Centers
Global Castration Resistant Prostate Cancer Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Castration Resistant Prostate Cancer Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Castration Resistant Prostate Cancer Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Castration Resistant Prostate Cancer Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals
